Lars Buschhorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lars Buschhorn has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Burkhard Schmidt
Gemeinschaftspraxis Hämato-Onkologie Pasing, Munich, Germany
1 shared publication - Catharina Müller-Thomas
Klinik für Hämatologie, Onkologie und Stammzelltransplantation, München Klinik Schwabing, München, Deutschland
1 shared publication - Christian Peschel
III Medical Department for Hematology and Oncology, Klinikum Rechts der Isar, Technische Universität München, 80333 Munich, Germany
1 shared publication - Dirk Hempel
Onkologisches Zentrum Donauwörth, Donauwörth, Germany
1 shared publication - Florian Bassermann
Department of Medicine III, TUM Klinikum, Technische Universität München, München, Germany
1 shared publication - Johanna Kauschinger
Medical Department III for Hematology and Oncology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 16 April 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 9
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.
- 16 April 2019
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 8 (1) , 9
Open AccessVenetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.